Patents by Inventor Narciso Costa

Narciso Costa has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20230181592
    Abstract: A compound of formula (I), for use in the treatment of non-traumatic acquired brain injury, in which M represents a NR1R2 group, an OR1 group or a SR1 group, A represents a NR4R5 group, an OR10 group or a hydrogen atom, R3 is a (C1-C6)alkyl group, a (C1-C6)cycloalkyl group, an aryl group, a —CH2-aryl group, a CH2-(C1-C6)cycloalkyl group or a —CH2-heteroaryl group, and its addition salts with pharmaceutically acceptable acids. A compound of formula (I) wherein R5 is a (C1-C8)alkyl group or a (C1-C6)cycloalkyl group, said alkyl and cycloalkyl group being substituted with one, two or three —OCORa group(s).
    Type: Application
    Filed: April 23, 2021
    Publication date: June 15, 2023
    Applicants: COMMISSARIAT A L'ENERGIE ATOMIQUE ET AUX ENERGIES ALTERNATIVES, WOMEN & INFANTS HOSPITAL OF RHODE ISLAND, SCIENTIAM PHARMA
    Inventors: Aloïse MABONDZO, Anne-Cécile GUYOT, Alain PRUVOST, Narciso COSTA, Hervé GALONS, Nassima OUMATA, Barbara STONESTREET, Clémence DISDIER
  • Patent number: 11312780
    Abstract: Antibodies directed against the endothelin receptor sub-type B, in particular monoclonal antibodies, a fragment or derivative thereof. The present disclosure also relates to the therapeutic, diagnostic use or as a research tool of such an antibody in the field of cancers and in particular glioblastoma.
    Type: Grant
    Filed: June 22, 2017
    Date of Patent: April 26, 2022
    Assignee: COMMISSARIAT À L'ÉNERGIE ATOMIQUE ET AUX ÉNERGIES ALTERNATIVES
    Inventors: Didier Boquet, Frédéric Ducancel, Amaury Herbet, Narciso Costa, Jean-Philippe Hugnot
  • Publication number: 20220089755
    Abstract: The present invention relates to antibodies against the endothelin receptor subtype A, in particular monoclonal antibodies, fragments or derivatives thereof. The present invention also relates to the therapeutic or diagnostic use of this antibody or as a research tool in the field of cancers, in particular glioblastoma.
    Type: Application
    Filed: February 4, 2019
    Publication date: March 24, 2022
    Applicants: COMMISSARIAT A L'ENERGIE ATOMIQUE ET AUX ENERGIES ALTERNATIVES, Universite de Paris, UNIVERSITE DE MONTPELLIER, Institut National de la Sante et de la recherche Medicale
    Inventors: Didier BOQUET, Amaury HERBET, Frederic DUCANCEL, Narciso COSTA, Jean-Yves COURAUD, Jean-Philippe HUGNOT
  • Publication number: 20190185574
    Abstract: Antibodies directed against the endothelin receptor sub-type B, in particular monoclonal antibodies, a fragment or derivative thereof. The present disclosure also relates to the therapeutic, diagnostic use or as a research tool of such an antibody in the field of cancers and in particular glioblastoma.
    Type: Application
    Filed: June 22, 2017
    Publication date: June 20, 2019
    Inventors: Didier Boquet, Frédéric Ducancel, Amaury Herbet, Narciso Costa, Jean-Philippe Hugnot